Tag: esophagitis
Eosinophilic esophagitis: symptoms and treatments for this inflammatory disease of the esophagus: Femme Actuelle Le MAG
Eosinophilic esophagitis is a rare chronic disease. It causes pain in the chest and abdomen, difficulty swallowing and heartburn. For a long time, doctors considered eosinophilic esophagitis to be a…
Sanofi: Positive data in esophagitis in children
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Sanofi: positive data in esophagitis in children
(CercleFinance.com) – Sanofi indicates that a phase III trial has demonstrated that the efficacy and safety profile of Dupixent, administered for a period of one year to children aged one…
Sanofi: positive data in esophagitis in children – 10/23/2023 at 07:43
(CercleFinance.com) – Sanofi indicates that a phase III trial has demonstrated that the efficacy and safety profile of Dupixent, administered for a period of one year to children aged one…
Sanofi: the only drug Dupixent for the treatment of eosinophilic esophagitis – 01/30/2023 at 09:38
(AOF) – The European Commission (EC) has extended the marketing authorization for Dupixent (dupilumab) in the European Union (EU) for the treatment of eosinophilic esophagitis in adults and adolescents from…
Sanofi: CHMP recommends EU approval of Dupixent for treatment of eosinophilic esophagitis
By Jean-Noel Legalland Published on 12/16/2022 at 1:48 p.m. Photo credit © Sanofi Corporate …
Sanofi: positive opinion from the CHMP in esophagitis – 12/16/2022 at 1:43 p.m.
(CercleFinance.com) – Sanofi announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of its Dupixent in the EU for the…
Sanofi: Positive data in esophagitis in children
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Sanofi: approval in esophagitis in the United States
(CercleFinance.com) – Sanofi announced Friday evening that the United States FDA has approved its Dupixent (dupilumab) 300 mg once weekly for the treatment of eosinophilic esophagitis in patients from the…
Sanofi: FDA approves Dupixent to treat eosinophilic esophagitis
PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi announced on Friday evening that the Food and Drug Administration (FDA), the American health authority, had authorized the use of its drug Dupixent for…
Sanofi: FDA grants priority review to Dupixent in eosinophilic esophagitis
PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi announced on Monday that the Food and Drug Administration (FDA), the American health authority, had agreed to grant a priority review to its drug…